Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in GNLX — GENELUX Corp

CIK 1423053 MIAMI, FL
Back to GNLX Full portfolio

Position in GNLX

as of Jun 30, 2026 · filed Sep 2, 2026
Position Value
$257,297
+$172,648 QoQ
Shares Held
85,481
+340.3% QoQ
Ownership
0.189%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#18
of 72 holders
Holding Since
Mar 2023
9 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in GNLX Over Time

Shares Held

Position Value (USD)

Derivatives in GNLX

reported options exposure · as of Sep 30, 2025
CallValue
$85,260
CallShares
20,300
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $6,150,758,606 across 435 Biotechnology names. GNLX ranks #301 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ONC
BeOne Medicines Ltd.
 1,425,517 $406,229,578
2 BBIO
BridgeBio Pharma, Inc.
 3,760,028 $280,046,885
3 INSM
INSMED Inc
 2,556,973 $272,624,460
4 MDGL
Madrigal Pharmaceuticals, Inc.
 507,233 $272,358,759
5 VRTX
Vertex Pharmaceuticals Inc / Ma
 510,430 $253,545,893
6 JAZZ
Jazz Pharmaceuticals plc
 1,006,676 $242,578,715
7 MANE
Veradermics, Inc
 1,877,775 $230,853,658
8 ROIV
Roivant Sciences Ltd.
 5,576,261 $197,343,876

All Filings in GNLX

Export CSV
11 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $257,297 85,481
2025-12-31 $84,649 19,415
2025-09-30 $85,260 20,300
2025-09-30 $143,820 34,243
2025-03-31 $156,303 57,890
2025-03-31 $27,270 10,100
2024-12-31 $45,911 19,454
2024-09-30 $138,800 58,566
2024-06-30 $29,076 14,911
2024-03-31 $287,806 44,760
2023-03-31 $294,460 10,615